STAT

3 trends to watch in pharma advertising in 2018

Can drug companies make you forget you're actually watching an ad? They're going to try. Check out our list of pharma marketing tactics to watch in 2018.

As the year winds down, STAT reporters are taking a look at the stories they’re most eager to track in 2018. Find all our “three to watch” series here

These are boom times for the multibillion-dollar drug advertising industry — and the parade of ads across your TV screen shows no sign of slowing down in 2018.

But while the money keeps flowing, there are changes

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.

Related